Literature DB >> 18340585

Prognostic factors for hypopharyngeal cancer: a univariate and multivariate study of 142 cases.

Masato Mochiki1, Masashi Sugasawa, Ken-Ichi Nibu, Masao Asai, Kazunari Nakao, Takahiro Asakage.   

Abstract

CONCLUSIONS: Reduction of distant metastases is essential for better survival. Effective adjuvant chemotherapy should be developed for patients with advanced primary disease (T>2) as well as for patients with advanced nodal status (N>0 or PLN>2).
OBJECTIVES: The aim of this study was to identify prognostic factors for hypopharyngeal cancer. PATIENTS AND METHODS: In all, 142 previously untreated patients were analyzed retrospectively; 75% of the cases were stage III or IV. Surgical resection was administered as primary treatment to 116 of the patients (82%), while 26 patients (18%) underwent primary radiotherapy.
RESULTS: The cause-specific 5-year actuarial survival was 46.3%. Distant metastases were the most frequent (23%) cause of failure, followed by local recurrence (15%), and regional recurrence (13%). Cox's regression analysis showed that the significant factors affecting cause-specific survival were N classification, T classification, number of pathological lymph node metastases (PLN), lymphatic invasion, and positive surgical margin. Similarly, T classification and PLN affected distant metastases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18340585     DOI: 10.1080/03655230701600095

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  2 in total

1.  Pyriform sinus squamous cell carcinoma: oncological outcomes in good responders of induction chemotherapy-based larynx preservation protocols.

Authors:  Zacharias Vourexakis; Anne-Marie Le Ridant; Pavel Dulguerov; François Janot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-23       Impact factor: 2.503

Review 2.  Mechanisms and Clinical Significance of Tumor Lymphatic Invasion.

Authors:  Noriki Fujimoto; Lothar C Dieterich
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.